Inflammatory markers and cardiovascular risk in healthy polish women across the menopausal transition

Clinical Chemistry

Volumn 51, Issue 10, 2005, Pages 1893-1895

  Stefánska, Anna ^a   Sypniewska, Grazyna ^a   Senterkiewicz, Lilla ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; SOLUBLE INTERCELLULAR ADHESION MOLECULE 1; SOLUBLE VASCULAR CELL ADHESION MOLECULE 1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLIMACTERIUM; CONTROLLED STUDY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; INSULIN RESISTANCE; MENOPAUSE; NORMAL HUMAN; OBESITY; POLAND; POSTMENOPAUSE;

BIOLOGICAL MARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MIDDLE AGED; PERIMENOPAUSE; POLAND; POSTMENOPAUSE; REFERENCE VALUES; REGRESSION ANALYSIS; RISK FACTORS;

EID: 25444456363     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2005.052191     Document Type: Article

References (18)

1. Davison S, Davis SR. New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J Clin Endocrinol Metab 2003;88:2470-8.
2. Howard BV, Hsia J, Ouyang P, Van Voorhees L, Lindsay J, Silverman A, et al. Postmenopausal hormone therapy is associated with atherosclerosis progression in women with abnormal glucose tolerance. Circulation 2004;110: 201-6.
3. Dudley EC, Hopper JL, Taffe J, Guthrie JR, Burger HG, Dennerstein L. Using longitudinal data to define the perimenopause by menstrual cycle characteristics. Climacteric 1998;1:18-25.
4. Sormova I, Dpnat J. Risk factors of metabolic estrogen-deficiency syndrome in women after menopause and its relationship to hormone replacement therapy. Ceska Gynekol 2004;69:388-96.
5. Cordero-MacIntyrez R, Lohman T, Rosen J, Peters W, Espana RC, Dickinson, et al. Weight loss is correlated with an improved lipoprotein profile in obese postmenopausal women. J Am Coll Nutr 2000;19:275-84.
6. Amant C, Holm P, Xu Sh SH, Tritmant N, Kearney M, Losordo DW. Estrogen receptor-mediated, nitric oxide-dependent modulation of the immunologic barrier function of the endothelium regulation of Fas ligand expression by estradiol. Circulation 2001;104:2576-81.
7. Wakatsuki A, Ikenoue N, Shinohara K, Watanabe K, Fukaya T. Effect of lower dosage of oral conjugated equine estrogen on inflammatory markers and endothelial function in healthy postmenopausal women. Arterioscler Thromb Vasc Biol 2004;24:571-6.
8. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-Reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.
9. Pradhan AD, Mansos JE, Rossouw JE, Siscovick DS, Mouton CP, Rifai N, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study: JAMA 2002;288:980-7.
10. Rifai N, Ridker PM. Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. Clin Chem 2001;47:28-30.
11. Rifai N, Ridker PM. Population distributions of C-reactive protein in apparently healthy men and women in the United States: implication for clinical interpretation. Clin Chem 2003;49:666-9.
12. Ponthieux A, Herbeth B, Droesch S, Haddy H, Lambert D, Visvikis S. Biological determinants of serum sICAM-1, E-selectin, P-selectin and L-selectin levels in healthy subjects: the Stanislas study. Atherosclerosis 2004;172:299-308.
13. Eschen O, Christensen JH, De Caterina R, Schmidt EB. Soluble adhesion molecules in healthy subjects. Nutr Metab Cardiovasc Dis 2004;14:180-5.
14. Stauffer BL, Hoetzer GL, Smith DT, DeSouza CA. Plasma C-reactive protein is not elevated in physically active postmenopausal women taking hormone replacement therapy. J Appl Physiol 2004;96:143-8.
15. Imhof A, Frohlich M, Loewel H, Helbecque N, Woodward M, Amouyel P, et al. Distribution of C-reactive protein measured by high-sensitivity assay in apparently healthy men and women from different populations in Europe. Clin Chem 2003;49:669-72.
16. Meade TW, Dyer S, Howarth DJ, Imeson JD, Stirling Y. Antithrombin III and procoagulant activity: sex differences and effects of the menopause. Br J Haematol 1990;74:77-81.
17. Sites CK, Toth MJ, Cushman M, L'Hommedieu GD, Tchernof A, Tracy RP. Menopause-related differences in inflammation markers and their relationship to body fat distribution and insulin-stimulated glucose disposal. Fertil Steril 2002;77:128-35.
18. Oger E, Alhene-Gelas M, Plu-Bureau G, Mennen L, Cambillau M, Guize L, et al. Association of circulating cellular adhesion molecules with menopausal status and hormone replacement therapy: time-dependent change in transdermal, but not oral estrogen users. Thromb Res 2001;101:35-43.